Akèy › Timò Nèwo-endokrin › Kentucky
Etid klinik pou Timò Nèwo-endokrin nan Kentucky
7 etid pou Timò Nèwo-endokrin ap chèche patisipan nan sit nan Kentucky.
Vil nan Kentucky
Tèks ofisyèl etid la (Anglè)
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- University of Kentucky Markey Cancer Center, Lexington
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06943755Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
- University of Kentucky Medical Center, Lexington
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07087054Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
- Research Facility, Lexington
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07165132Project: Every Child for Younger Patients With Cancer
- University of Kentucky/Markey Cancer Center, Lexington
- Norton Children's Hospital, Louisville
Ap rekriteEtid obsèvasyon
Jiska laj 25 · Tout sèks · Mizajou Aug 25, 2026 · NCT02402244A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Crinetics Study Site, Lexington
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT07129252Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- University of Kentucky, Lexington
Ap rekriteFaz 1/2
Laj 18 a 90 · Tout sèks · Mizajou May 14, 2026 · NCT05636618Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
- Research Facility, Lexington
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Mar 30, 2026 · NCT05477576Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.